Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines

References

• Friedberg JW, Cohen P, Chen L, . Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204–210.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Al-Batran SE, Kim SZ, . Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23:3383–3389.
   PubMed Web of Science ®Google Scholar
• Bergmann MA, Goebeler ME, Herold M, . Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005;90:1357–1364.
   PubMed Web of Science ®Google Scholar
• Knop S, Straka C, Haen M, . The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90:1287–1288.
   PubMed Web of Science ®Google Scholar
• Ponisch W, Mitrou PS, Merkle K, . Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006;132:205–212.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Chernozemsky I, Sirakova L, . Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 2005;16:871–877.
   PubMed Web of Science ®Google Scholar
• Schmittel A, Knodler M, Hortig P, . Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 2007;55:109–113.
   PubMed Web of Science ®Google Scholar
• Koster W, Heider A, Niederle N, . Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer. J Thorac Oncol 2007;2:312–316.
   PubMed Web of Science ®Google Scholar
• Leoni LM, Bailey B, Reifert J, . Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14:309–317.
   PubMed Web of Science ®Google Scholar
• Strumberg D, Harstrick A, Doll K, . Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996;7:415–421.
   PubMed Web of Science ®Google Scholar
• Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol 2002;128:603–609.
   PubMed Web of Science ®Google Scholar
• Leoni LM, Niemeyer CC, Kerfoot C, . In vitro and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells. Proc Am Assoc Cancer Res 2004;45: Abstract 1215.
   Google Scholar
• Chou TC, Arlin Z, Clarkson BD, . Metabolism of 1-beta-D-arabinofuranosylcytosine in human leukemic cells. Cancer Res 1977;37:3561–3570.
   PubMed Web of Science ®Google Scholar
• Kessel D, Hall TC, Wodinsky I. Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside. Science 1967;156:1240–1241.
   PubMed Web of Science ®Google Scholar
• Kufe DW, Major PP, Egan EM, . Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem 1980;255:8997–8900.
   PubMed Web of Science ®Google Scholar
• Spriggs D, Robbins G, Ohno Y, . Detection of 1-beta-D-arabinofuranosylcytosine incorporation into DNA in vivo. Cancer Res 1987;47:6532–6536.
   PubMed Web of Science ®Google Scholar
• Peters WG, Colly LP, Willemze R. High-dose cytosine arabinoside: pharmacological and clinical aspects. Blut 1988;56:1–11.
   PubMedGoogle Scholar
• Gandhi V, Estey E, Keating MJ, . Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993;11:116–124.
   PubMed Web of Science ®Google Scholar
• Staib P, Schinkothe T, Dimsky T, . In vitro modulation of Ara-ctp accumulation in fresh AML cells by bendamustine in comparison with fludarabine, 2-CdA and gemcitabine. Blood 1999;94(Suppl. 1): Abstract 271.
   Google Scholar
• Chow KU, Boehrer S, Napieralski S, . In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential. Leuk Lymphoma 2003;44: 165–173.
   PubMed Web of Science ®Google Scholar
• Visco C, Castegnaro S, Chieregato K, . The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells Mol Dis 2012;48:68–75.
   PubMed Web of Science ®Google Scholar
• Robinson KS, Williams ME, van der Jagt RH, . Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473–4479.
   PubMed Web of Science ®Google Scholar
• Schwänen C, Hecker T, Hubinger G, . In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 2002;16:2096–2105.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, . Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29:3559–3566.
   PubMed Web of Science ®Google Scholar
• Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol 2002; 29(Suppl. 13):4–11.
   PubMed Web of Science ®Google Scholar
• Visco C, Lissandrini L, Zambello R, . Rituximab, bendamustine and cytarabine (R-BAC) is a very active regimen in patients with mantle cell lymphoma not eligible for intensive chemotherapy or autologous transplant. Ann Oncol 2011;22(Suppl. 4): Abstract 236.
   Google Scholar